10-K: Cibus Inc. 2023 Annual Report: Strategic Realignment and Focus on Commercialization

Cibus Inc.'s 2023 annual report highlights a strategic shift towards commercialization, marked by a merger, cost reductions, and advancements in its gene editing technology.

Summary

• Cibus Inc. completed a merger with Cibus Global, combining their gene editing technologies.
• The company is focusing on commercializing its five-trait pipeline, with three traits already transferred to seed company partners.
• A strategic realignment led to a reduction in workforce and cost-cutting measures.
• The company incurred a net loss of $337.6 million for the year ended December 31, 2023.
• Cibus has $32.7 million in cash and cash equivalents as of December 31, 2023, and has substantial doubt about its ability to continue as a going concern.
• The company is dependent on raising additional capital to fund its operations.
• Cibus is developing a high-throughput gene editing system called the Trait Machine process.
• The company has established crop platforms in Canola, Rice, and Wheat, with Soybean platform development underway.
• Cibus is licensing its productivity traits to seed companies in return for royalty payments.
• The company's technology is non-transgenic, which is expected to be regulated similarly to conventional breeding in many jurisdictions.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in technology and commercialization, the significant losses, going concern uncertainty, and need for additional capital raise concerns for investors.

Positives

• The merger with Cibus Global has created a leader in precision gene editing.
• Cibus has successfully transferred three developed traits to leading seed companies.
• The company has established a scalable gene editing process in Wheat.
• Cibus's Trait Machine process is a standardized, high-throughput system that can directly edit a customer's elite germplasm.
• The company's non-transgenic technology is expected to be regulated similarly to conventional breeding in many jurisdictions.
• Cibus has a pipeline of five productivity traits, four of which are applicable to multiple crops.
• The company has a capital-efficient and highly scalable business model.

Negatives

• Cibus has incurred significant losses and anticipates continuing to incur losses for several years.
• The company has substantial doubt about its ability to continue as a going concern.
• Cibus faces significant competition from companies with greater financial resources.
• The company's success depends on its ability to effectively estimate future demand.
• Cibus's business activities are currently conducted at a limited number of locations.
• The company's research and development efforts may be slower than expected and not be successful.
• Cibus is dependent on third parties to successfully commercialize its products.
• The company's products may not achieve commercial success quickly or at all.
• Cibus is subject to governmental export and import controls that could impair its ability to compete in international markets.
• The market price of the Class A Common Stock has been and could remain volatile.

Risks

• Cibus's ability to continue as a going concern depends on obtaining additional financing.
• The company faces significant competition from companies with greater financial resources.
• Cibus's success depends on its ability to effectively estimate future demand.
• The company's research and development efforts may be slower than expected and not be successful.
• Cibus is dependent on third parties to successfully commercialize its products.
• The company's products may not achieve commercial success quickly or at all.
• Public perception and acceptance of gene editing technologies could affect Cibus sales.
• Regulatory requirements for gene edited products are evolving and could have a negative impact.
• Cibus is subject to governmental export and import controls that could impair its ability to compete in international markets.
• The company's ability to compete may decline if it does not adequately protect its intellectual property rights.
• The market price of the Class A Common Stock has been and could remain volatile.
• Cibus is a holding company and its only material asset is its interest in Cibus Global, and it is accordingly dependent upon distributions from Cibus Global to pay taxes, make payments under the Tax Receivable Agreement, and cover its corporate and other overhead expenses.

Future Outlook

Cibus expects to continue to incur significant expenses and operating losses for at least the next several years. The company will need to raise additional capital to support its business plans to continue as a going concern within one year after the date that the accompanying financial statements are issued.

Management Comments

• Cibus believes that its RTDS technologies and Trait Machine process represent a technological breakthrough in plant breeding.
• Cibus believes that its gene editing technologies and trait products have the potential to accelerate agricultures jump to a climate smart, more sustainable crop production system.
• Cibus believes that its Trait Machine process is unique in its ability to materially change the scale and speed of trait development and commercialization.
• Cibus believes that its gene edits are indistinguishable from genetic changes that could occur from conventional breeding or that could occur in nature.

Industry Context

The report highlights the evolving regulatory landscape for gene editing technologies, with a global movement towards regulating gene edited traits similarly to those developed through conventional breeding. This is a significant shift from the heavily regulated GMO technology and is a key factor in Cibus's strategy and future outlook.

Comparison to Industry Standards

• The report references AgBioInvestor estimates for the Bt trait, a GMO trait for insect resistance, which earns $10-$20 per acre in trait fees, with aggregate trait fees estimated at approximately $2.6 billion in corn, $0.7 billion in cotton, and $0.5 billion in soy. This provides a benchmark for the potential value of Cibus's traits.
• The report also mentions that GMO-based weed management traits are planted on over 300 million acres and earn annual trait fees of approximately $4.0 billion, which is another benchmark for the potential value of Cibus's traits.
• The report notes that Cibus estimates that for every dollar of trait royalty, a farmer receives approximately a two-fold benefit in cost and yield improvement, which is a key factor in the value proposition of Cibus's traits.
• The report compares Cibus's Sclerotinia resistance trait to the Bt trait, noting that the severity of Sclerotinia stem rot can be significant, and that Cibus estimates that approximately 30 million acres of canola could be impacted by Sclerotinia stem rot. This provides a basis for the potential value of the Sclerotinia resistance trait.

Related Party Transactions

• Certain directors and officers of Cibus are beneficiaries of the Royalty Liability.
• Cellectis has guaranteed the lease agreement for the Companys Roseville, Minnesota facility, and the Company has agreed to indemnify Cellectis for any obligations under this guaranty.
• The Company holds a license from Cellectis that broadly covers the use of engineered nucleases for plant gene editing.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional capital.
• Employees have experienced a reduction in workforce as part of the strategic realignment.
• Customers (seed companies) will benefit from the new traits developed by Cibus.
• The company's suppliers and service providers may be affected by the cost reduction measures.
• Creditors may be impacted by the company's financial instability and need for additional capital.

Next Steps

• Cibus will focus on completing the launch of its first three traitsPSR, HT1, and HT3in its crop programs in Canola, WOSR, and Rice.
• The company will enable its Soybean platform.
• Cibus will advance its Sclerotinia resistance trait and HT2 trait in Canola, WOSR, and Soybean.
• The company will continue to evaluate a full range of strategic alternatives to maximize shareholder value, which may include potential equity or debt financing transactions, business combination transactions, sales of assets, licensing, and other strategic transactions.

Key Dates

Keywords

gene editing, plant traits, productivity traits, agriculture, biotechnology, RTDS, Trait Machine, commercialization, seed companies, non-transgenic